NDA 021856 · Takeda Pharms USA
Uloric
Febuxostat · Oral · Xanthine Oxidase Inhibitor
NovelLast checked: Nov 20, 2026Latest source record: Apr 17, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Feb 13, 2009
Approved uses
3
Original approval plus efficacy supplements
Registered trials
108
21 Phase 3, 9 recruiting
FAERS reports
17,000
12,910 serious, 2,242 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CARDIOVASCULAR DEATH Gout patients with established cardiovascular (CV) disease treated with ULORIC had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study [see Warnings and Precautions (5.1) ] . Consider the risks and benefits of ULORIC when deciding to prescribe or continue patients on ULORIC. ULORIC should only be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable [see Indications and Usage (1) ] . WARNING: CARDIOVASCULAR DEATH See full prescribing information for complete boxed warning. Gout patients with established cardiovascular (CV) disease treated with ULORIC had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study. ( 5.1 ) Consider the risks and benefits of...
What it is approved for
From the label in effect Dec 24, 2025.
ULORIC is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. ULORIC is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. ( 1 ) Limitations of Use : ULORIC is not recommended for the treatment of asymptomatic hyperuricemia. ( 1 ) Limitations of Use : ULORIC is not recommended for the treatment of asymptomatic hyperuricemia.
Mechanism: ULORIC, a xanthine oxidase inhibitor, achieves its therapeutic effect by decreasing serum uric acid. ULORIC is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 21, 2019 Supplement 13 · Efficacy LabelLetter
- Aug 15, 2017 Supplement 11 · Efficacy LabelLetter
- Feb 13, 2009 Original approval · Type 1 - New Molecular Entity NovelReviewLabelSummary Review
2 products under this application
- ULORIC · FEBUXOSTAT 80MG · TABLET, ORAL · Prescription · TE AB
- ULORIC · FEBUXOSTAT 40MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Febuxostat" as an intervention, any sponsor and status, largest first.
- Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT01101035 · 6,198 participants · Start Apr 23, 2010 · Primary completion May 15, 2017
Drug: Febuxostat; Allopurinol · For: Cardiovascular Disease
Sites: Decatur, Georgia; Dunwoody, Georgia; Marietta, Georgia · 203 sites in all
- Efficacy and Safety of Oral Febuxostat in Participants With GoutPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00430248 · 2,269 participants · Start Feb 2007 · Primary completion Mar 2008
Drug: Febuxostat; Febuxostat and 1 more · For: Gout
Sites: Birmingham, Alabama; Hoover, Alabama; Hueytown, Alabama · 258 sites in all
- Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With GoutPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT02139046 · 1,790 participants · Start Apr 2014 · Primary completion Nov 2015
Drug: Febuxostat IR; Febuxostat XR and 4 more · For: Gout
Sites: Binghamton, Alabama; Birmingham, Alabama; Huntsville, Alabama · 192 sites in all
- Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00175019 · 1,086 participants · Start Jul 2003 · Primary completion Feb 2007
Drug: Febuxostat; Febuxostat and 1 more · For: Gout
- Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00174915 · 1,072 participants · Start Feb 2003 · Primary completion Apr 2004
Drug: Febuxostat; Febuxostat and 3 more · For: Gout
- Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDyPivotal-lookingStatus unknown
Freed Study GroupAcademic, hospital or other
NCT01984749 · 1,000 participants (planned) · Start Nov 2013 · Primary completion Oct 2017
Drug: Febuxostat · For: Hyperuricemia
Sites: Nagoya, Japan; Yurihonjō, Japan; Matsudo, Japan · 140 sites in all
- CSP594 Comparative Effectiveness in Gout: Allopurinol vs. FebuxostatPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT02579096 · 950 participants · Start Mar 6, 2017 · Primary completion Feb 1, 2021
Drug: allopurinol capsule, 100-800 mg by mouth once daily; febuxostat tablet 40-120 mg by mouth once daily and 2 more · For: Gout; Chronic Kidney Diseases
Sites: Loma Linda, California; San Diego, California; San Francisco, California · 23 sites in all
- Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese PatientsPivotal-lookingStatus unknown
Shanghai 10th People's HospitalAcademic, hospital or other
NCT02944214 · 800 participants (planned) · Start Oct 2016 · Primary completion Dec 2019
Drug: Febuxostat; Benzbromarone · For: Chronic Kidney Disease; Hyperuricemia; Abnormal Renal Function
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea904
- acute kidney injury881
- nausea870
- rash812
- off label use772
- drug ineffective709
- gout700
- dyspnoea651
- fatigue628
- headache599
- anaemia598
- pneumonia569
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 73 |
| 2010 | 105 |
| 2011 | 196 |
| 2012 | 226 |
| 2013 | 294 |
| 2014 | 356 |
| 2015 | 2,414 |
| 2016 | 863 |
| 2017 | 867 |
| 2018 | 1,045 |
| 2019 | 1,142 |
| 2020 | 1,165 |
| 2021 | 1,431 |
| 2022 | 1,668 |
| 2023 | 1,474 |
| 2024 | 1,466 |
| 2025 | 1,325 |
| 2026 | 890 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Uloric (Febuxostat)
2024 spending
$4.1M
Beneficiaries
1,723
7,458 claims
Per beneficiary
$2,398
$10.32 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $17,641,167 |
| 2021 | $10,402,721 |
| 2022 | $7,851,519 |
| 2023 | $6,049,573 |
| 2024 | $4,132,481 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- 2016 updated EULAR evidence-based recommendations for the management of gout.
Richette P, Doherty M, Pascual E, et al. · Ann Rheum Dis 2017 · Practice Guideline, Systematic Review
- Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA, Schumacher HR, Wortmann RL, et al. · N Engl J Med 2005 · Clinical Trial, Phase III, Comparative Study
- Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB, Saag KG, Becker MA, et al. · N Engl J Med 2018 · Comparative Study, Equivalence Trial
- Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, et al. · Lancet 2020 · Multicenter Study, Randomized Controlled Trial
- Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis.
Deng JH, Lai PH, Xie LS, et al. · Clin Transl Sci 2024 · Systematic Review, Meta-Analysis
- Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China.
Sun J, Wang Y, Cheng Y, et al. · Arthritis Rheumatol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.